{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,9,1]],"date-time":"2026-09-01T16:47:17Z","timestamp":1788281237593,"version":"build-2803163510"},"reference-count":46,"publisher":"Wiley","issue":"24","license":[{"start":{"date-parts":[[2023,12,6]],"date-time":"2023-12-06T00:00:00Z","timestamp":1701820800000},"content-version":"vor","delay-in-days":5,"URL":"http:\/\/creativecommons.org\/licenses\/by\/4.0\/"}],"content-domain":{"domain":["onlinelibrary.wiley.com"],"crossmark-restriction":true},"short-container-title":["Cancer Medicine"],"published-print":{"date-parts":[[2023,12]]},"abstract":"<jats:title>Abstract<\/jats:title><jats:sec><jats:title>Objectives<\/jats:title><jats:p>To assess the occurrence of cardiotoxicity in patients with tumors receiving anthracycline\u2010based chemotherapy, especially for sarcomas.<\/jats:p><\/jats:sec><jats:sec><jats:title>Methods<\/jats:title><jats:p>This study summarized the types and frequency of adverse events (AEs) for three anthracyclines from the FDA adverse event reporting system (FAERS) database. FAERS data from January 2004 to June 2022 were collected and analyzed. Disproportionality analyses, logistic regression, and descriptive analysis were used to compare the differences in cardiac disorders. A retrospective cohort study was conducted in a single center between December 2008 and May 2022. Our hospital\u2010treated patients with bone and soft tissue sarcomas (BSTSs) with anthracycline\u2010containing chemotherapy were analyzed. Serum markers, echocardiography, and electrocardiography have been used to evaluate cardiotoxic events.<\/jats:p><\/jats:sec><jats:sec><jats:title>Results<\/jats:title><jats:p>One hundred thousand and seventy\u2010five AE reports were obtained for doxorubicin (ADM), epirubicin (EPI), and liposome doxorubicin (L\u2010ADM) from the FAERS database. ADM (OR\u2009=\u20093.1, <jats:italic>p<\/jats:italic>\u2009&lt;\u20090.001), EPI (OR\u2009=\u20091.5, <jats:italic>p<\/jats:italic>\u2009&lt;\u20090.001), and sarcomas (OR\u2009=\u20091.8, <jats:italic>p<\/jats:italic>\u2009&lt;\u20090.001) may increase the probability of cardiac disorders. Cardiac failure, cardiotoxicity, and cardiomyopathy were anthracyclines' top 3 frequent AEs. Among patients receiving ADM\u2010containing therapy, those with ADM applied at doses \u226575\u2009mg\/m<jats:sup>2<\/jats:sup>\/cycle were more likely to develop cardiac disorders than the other subgroups (OR\u2009=\u20093.5, <jats:italic>p<\/jats:italic>\u2009&lt;\u20090.001). Patients younger than 18 are more likely to benefit from dexrazoxane prevention of cardiac failure. Six hundred and eighty\u2010three patients with BSTSs receiving anthracycline\u2010based chemotherapy were analyzed in our center. Patients receiving ADM\u2010containing chemotherapy were likelier to experience abnormalities in serum troponin\u2010T and left ventricular ejection fraction (<jats:italic>p<\/jats:italic>\u2009&lt;\u20090.05). 2.0% (6\/300) of patients receiving ADM\u2010containing chemotherapy required adjustment of the chemotherapy regimen because of cardiotoxicity, whereas none were in the EPI or L\u2010ADM groups.<\/jats:p><\/jats:sec><jats:sec><jats:title>Conclusions and Relevance<\/jats:title><jats:p>Among patients receiving anthracycline\u2010containing therapy, patients with BSTSs were more likely to develop cardiac disorders than other tumors. In addition, patients with BSTSs receiving ADM chemotherapy had a higher likelihood of cardiotoxic events than those receiving EPI or L\u2010ADM.<\/jats:p><\/jats:sec>","DOI":"10.1002\/cam4.6730","type":"journal-article","created":{"date-parts":[[2023,12,6]],"date-time":"2023-12-06T09:00:43Z","timestamp":1701853243000},"page":"21709-21724","update-policy":"https:\/\/doi.org\/10.1002\/crossmark_policy","source":"Crossref","is-referenced-by-count":12,"title":["Evaluation of cardiotoxicity of anthracycline\u2010containing chemotherapy regimens in patients with bone and soft tissue sarcomas: A study of the FDA adverse event reporting system joint single\u2010center real\u2010world experience"],"prefix":"10.1002","volume":"12","author":[{"ORCID":"https:\/\/orcid.org\/0000-0002-0476-7618","authenticated-orcid":false,"given":"Zeming","family":"Mo","sequence":"first","affiliation":[{"name":"Division of Medical Oncology, Cancer Center, West China Hospital Sichuan University  Chengdu China"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Yaotiao","family":"Deng","sequence":"additional","affiliation":[{"name":"Division of Medical Oncology, Cancer Center, West China Hospital Sichuan University  Chengdu China"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Yiwen","family":"Bao","sequence":"additional","affiliation":[{"name":"Department of Oncology The People's Hospital of Qiannan  Duyun Guizhou China"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-6266-4449","authenticated-orcid":false,"given":"Jie","family":"Liu","sequence":"additional","affiliation":[{"name":"Division of Medical Oncology, Cancer Center, West China Hospital Sichuan University  Chengdu China"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0003-0716-4334","authenticated-orcid":false,"given":"Yu","family":"Jiang","sequence":"additional","affiliation":[{"name":"Division of Medical Oncology, Cancer Center, West China Hospital Sichuan University  Chengdu China"}],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"311","published-online":{"date-parts":[[2023,12,6]]},"reference":[{"key":"e_1_2_11_2_1","doi-asserted-by":"publisher","DOI":"10.1111\/echo.13871"},{"key":"e_1_2_11_3_1","doi-asserted-by":"publisher","DOI":"10.1200\/EDBK_100015"},{"key":"e_1_2_11_4_1","doi-asserted-by":"publisher","DOI":"10.1016\/j.jconrel.2012.03.020"},{"key":"e_1_2_11_5_1","doi-asserted-by":"publisher","DOI":"10.1007\/s10637-007-9069-0"},{"key":"e_1_2_11_6_1","doi-asserted-by":"publisher","DOI":"10.1007\/978-3-030-43032-0_15"},{"key":"e_1_2_11_7_1","doi-asserted-by":"publisher","DOI":"10.1161\/JAHA.118.009122"},{"key":"e_1_2_11_8_1","doi-asserted-by":"publisher","DOI":"10.1007\/s11764-021-01028-4"},{"issue":"9","key":"e_1_2_11_9_1","article-title":"Dexrazoxane for preventing or reducing cardiotoxicity in adults and children with cancer receiving anthracyclines","volume":"9","author":"Baat EC","year":"2022","journal-title":"Cochrane Database Syst Rev"},{"key":"e_1_2_11_10_1","doi-asserted-by":"publisher","DOI":"10.1590\/1806-9282.64.08.745"},{"key":"e_1_2_11_11_1","doi-asserted-by":"publisher","DOI":"10.1186\/1471-2407-10-337"},{"key":"e_1_2_11_12_1","article-title":"Different anthracycline derivates for reducing cardiotoxicity in cancer patients","volume":"2010","author":"Dalen EC","year":"2010","journal-title":"Cochrane Database Syst Rev"},{"key":"e_1_2_11_13_1","doi-asserted-by":"publisher","DOI":"10.1002\/(SICI)1097-0142(19980601)82:11<2282::AID-CNCR26>3.0.CO;2-P"},{"key":"e_1_2_11_14_1","doi-asserted-by":"publisher","DOI":"10.1016\/S2352-3026(19)30051-1"},{"issue":"2","key":"e_1_2_11_15_1","first-page":"261","article-title":"Phase II study of doxorubicin versus epirubicin in advanced breast cancer","volume":"70","author":"Brambilla C","year":"1986","journal-title":"Cancer Treat Rep"},{"key":"e_1_2_11_16_1","doi-asserted-by":"publisher","DOI":"10.1093\/annonc\/mdh097"},{"key":"e_1_2_11_17_1","doi-asserted-by":"publisher","DOI":"10.1016\/j.ijcard.2012.10.079"},{"key":"e_1_2_11_18_1","doi-asserted-by":"publisher","DOI":"10.1002\/cncr.10201"},{"key":"e_1_2_11_19_1","doi-asserted-by":"publisher","DOI":"10.1016\/j.ejca.2016.02.004"},{"key":"e_1_2_11_20_1","doi-asserted-by":"publisher","DOI":"10.1002\/cam4.3730"},{"key":"e_1_2_11_21_1","doi-asserted-by":"publisher","DOI":"10.1200\/JCO.19.03289"},{"key":"e_1_2_11_22_1","doi-asserted-by":"publisher","DOI":"10.1016\/S1470-2045(17)30622-8"},{"key":"e_1_2_11_23_1","doi-asserted-by":"publisher","DOI":"10.1186\/s13018-020-1576-0"},{"key":"e_1_2_11_24_1","doi-asserted-by":"publisher","DOI":"10.1158\/1078-0432.CCR-20-4592"},{"key":"e_1_2_11_25_1","doi-asserted-by":"publisher","DOI":"10.1158\/1078-0432.CCR-22-1903"},{"key":"e_1_2_11_26_1","doi-asserted-by":"publisher","DOI":"10.1016\/j.jaccao.2019.10.006"},{"key":"e_1_2_11_27_1","doi-asserted-by":"publisher","DOI":"10.1177\/1078155215621150"},{"issue":"4","key":"e_1_2_11_28_1","article-title":"Efficacy of dexrazoxane in cardiac protection in pediatric patients treated with anthracyclines","volume":"15","author":"Rahimi P","year":"2023","journal-title":"Cureus"},{"key":"e_1_2_11_29_1","doi-asserted-by":"publisher","DOI":"10.1161\/CIRCULATIONAHA.114.013777"},{"key":"e_1_2_11_30_1","doi-asserted-by":"publisher","DOI":"10.1093\/annonc\/mdx773"},{"key":"e_1_2_11_31_1","doi-asserted-by":"publisher","DOI":"10.1002\/pds.668"},{"key":"e_1_2_11_32_1","unstructured":"Couch DRaAHaS.Broom: Convert Statistical Objects into Tidy Tibbles.2023.https:\/\/CRAN.R\u2010project.org\/package=broom"},{"key":"e_1_2_11_33_1","first-page":"2053","volume-title":"Statistics in Medicine","author":"Borgan \u00d8","year":"2000"},{"key":"e_1_2_11_34_1","doi-asserted-by":"publisher","DOI":"10.1093\/eurheartj\/ehad196"},{"key":"e_1_2_11_35_1","doi-asserted-by":"publisher","DOI":"10.1016\/j.amjcard.2015.04.064"},{"key":"e_1_2_11_36_1","doi-asserted-by":"publisher","DOI":"10.1002\/pbc.25651"},{"key":"e_1_2_11_37_1","doi-asserted-by":"publisher","DOI":"10.1007\/s10549-011-1558-3"},{"key":"e_1_2_11_38_1","doi-asserted-by":"publisher","DOI":"10.3389\/fbioe.2022.953555"},{"issue":"12","key":"e_1_2_11_39_1","first-page":"6387","article-title":"A new concept for macromolecular therapeutics in cancer chemotherapy: mechanism of tumoritropic accumulation of proteins and the antitumor agent smancs","volume":"46","author":"Matsumura Y","year":"1986","journal-title":"Cancer Res"},{"key":"e_1_2_11_40_1","doi-asserted-by":"publisher","DOI":"10.3389\/fonc.2022.921983"},{"key":"e_1_2_11_41_1","doi-asserted-by":"publisher","DOI":"10.1039\/D1TB00566A"},{"key":"e_1_2_11_42_1","doi-asserted-by":"publisher","DOI":"10.1080\/10717544.2021.1945167"},{"key":"e_1_2_11_43_1","doi-asserted-by":"publisher","DOI":"10.1186\/s13046-020-01548-4"},{"key":"e_1_2_11_44_1","doi-asserted-by":"publisher","DOI":"10.1002\/cmdc.202100464"},{"key":"e_1_2_11_45_1","doi-asserted-by":"publisher","DOI":"10.1021\/acsami.1c04081"},{"key":"e_1_2_11_46_1","doi-asserted-by":"publisher","DOI":"10.1080\/1120009X.2021.1913703"},{"key":"e_1_2_11_47_1","doi-asserted-by":"publisher","DOI":"10.1155\/S1357714X00000062"}],"container-title":["Cancer Medicine"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/onlinelibrary.wiley.com\/doi\/pdf\/10.1002\/cam4.6730","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2024,1,14]],"date-time":"2024-01-14T08:54:24Z","timestamp":1705222464000},"score":1,"resource":{"primary":{"URL":"https:\/\/onlinelibrary.wiley.com\/doi\/10.1002\/cam4.6730"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2023,12]]},"references-count":46,"journal-issue":{"issue":"24","published-print":{"date-parts":[[2023,12]]}},"alternative-id":["10.1002\/cam4.6730"],"URL":"https:\/\/doi.org\/10.1002\/cam4.6730","archive":["Portico"],"relation":{},"ISSN":["2045-7634","2045-7634"],"issn-type":[{"value":"2045-7634","type":"print"},{"value":"2045-7634","type":"electronic"}],"subject":[],"published":{"date-parts":[[2023,12]]},"assertion":[{"value":"2023-08-18","order":0,"name":"received","label":"Received","group":{"name":"publication_history","label":"Publication History"}},{"value":"2023-11-07","order":1,"name":"accepted","label":"Accepted","group":{"name":"publication_history","label":"Publication History"}},{"value":"2023-12-06","order":2,"name":"published","label":"Published","group":{"name":"publication_history","label":"Publication History"}}]}}